Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anaptysbio Inc

18.97
+0.57003.10%
Post-market: 18.970.00000.00%16:05 EDT
Volume:548.40K
Turnover:10.53M
Market Cap:581.75M
PE:-3.71
High:19.82
Open:18.10
Low:17.99
Close:18.40
Loading ...

Vanda Pharmaceuticals Inc: Anaptys to Receive $15 Mln From Vanda, Comprised of a $10 Mln Upfront Payment and $5 Mln for Existing Drug Supply

THOMSON REUTERS
·
03 Feb

Vanda Pharmaceuticals Inc: Anaptys to Receive a 10% Royalty on Global Net Sales of Imsidolimab

THOMSON REUTERS
·
03 Feb

AnaptysBio (ANAB) Receives a Buy from TD Cowen

TIPRANKS
·
29 Jan

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Zacks
·
27 Jan

Leerink Partners Remains a Buy on AnaptysBio (ANAB)

TIPRANKS
·
20 Jan

Big Biotech Fund Bought a Stock That Surged, and a Loser -- Barron's

Dow Jones
·
18 Jan

How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

Zacks
·
13 Jan

Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser -- Barrons.com

Dow Jones
·
12 Jan

NVIDIA DRIVE Hyperion Platform Achieves Critical Automotive Safety and Cybersecurity Milestones for AV Development

GlobeNewswire
·
07 Jan

AnaptysBio Is Maintained at Overweight by JP Morgan

Dow Jones
·
20 Dec 2024

AnaptysBio Inc : Truist Securities Cuts Target Price to $20 From $30

THOMSON REUTERS
·
19 Dec 2024

U.S. RESEARCH ROUNDUP- Amazon, Mastercard, Tesla

Reuters
·
19 Dec 2024

AnaptysBio price target lowered to $20 from $30 at Truist

TIPRANKS
·
18 Dec 2024

Truist Securities Cuts Price Target on AnaptysBio to $20 From $30, Maintains Hold Rating

MT Newswires Live
·
18 Dec 2024

Stifel Nicolaus Sticks to Their Buy Rating for AnaptysBio (ANAB)

TIPRANKS
·
17 Dec 2024

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)

TIPRANKS
·
16 Dec 2024

UBS Adjusts AnaptysBio Price Target to $18 From $33, Maintains Neutral Rating

MT Newswires Live
·
13 Dec 2024

AnaptysBio Inc : UBS Cuts Target Price to $18 From $33

THOMSON REUTERS
·
13 Dec 2024

AnaptysBio Is Maintained at Overweight by Wells Fargo

Dow Jones
·
13 Dec 2024

AnaptysBio (NASDAQ:ANAB investor three-year losses grow to 55% as the stock sheds US$261m this past week

Simply Wall St.
·
13 Dec 2024